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Sepsis, which may be defined as the systemic illness caused 
by the suspected invasion of normally sterile parts of the body 
by microbial organisms, is a major healthcare problem, ranking 
among the top ten causes of death. This article reviews the evidence 
behind the general and specific measures in the management of 
sepsis, based on the Surviving Sepsis Campaign Guidelines.
whaT is sePsis, anD why is iT imPorTanT?
Sepsis is a major healthcare problem, affecting millions 
of people worldwide, occurring at all ages and in different 
patient groups, from healthy individuals in the community to 
ill hospitalized patients.1 Sepsis may be defined as the systemic 
illness caused by the suspected invasion of normally sterile parts 
of the body by microbial organisms. Sepsis leading to acute organ 
dysfunction or tissue hypoperfusion is defined as severe sepsis, 
and severe sepsis resulting in hypotension not reversed with fluid 
resuscitation is septic shock. This definition of sepsis specifically 
distinguishes it from the similar clinical picture of systemic 
inflammatory response syndrome (SIRS) that arises without an 
underlying infection but secondary to, for example, pancreatitis 
and anaphylaxis. The similarity of these syndromes is due to the 
same underlying deleterious host response resulting in the same 
pathophysiological pathways and release of cytokines and other 
inflammatory peptides.2
The PaThoPhysiology anD clinical PresenTaTion of sePsis: from 
PaThogen enTry To sePTic shock
The first barrier to infection is the continuous membrane of 
the skin, and the internal mucous membranes of the respiratory, 
genitourinary and gastrointestinal tract. Loss of integrity may 
be obvious as in the case of severe burns, or an anastomotic leak 
following surgery, but it may also be subtle as in the case of an 
insect bite. In a hospital environment such loss of integrity is 
often due to the use of intravenous cannulas, catheters, drains and 
other devices. once an organism has gained entry, it prompts a 
regional immune response mediated by various cellular, cytokine 
and other inflammatory peptide-controlled mechanisms. The 
release of these effector peptides such as tNF-α, interleukins 
and prostaglandins results in a cascade of regional, followed by 
a systemic, inflammatory response. Clinically, this inflammatory 
response results in the clinical features and presentation of sepsis. 
The features of this response are very variable as it is a combination 
of organism virulence and burden, together with the host response 
factors.
The diagnostic criteria for sepsis is therefore documented as 
suspected infection together with some of the following features 
which characterize a systemic inflammatory response.
a. general variables:
•	 Fever	>38°C
•	 Hypothermia	<36°C
•	 Heart	rate		>90/min
•	 Tachypnea
•	 Altered	mental	status
•	 Significant	edema	or	positive	fluid	balance
•	 Hyperglycemia	i.e.	>7.7	mmol/L	in	the	absence	of	pre-existing	
diabetes
b. inflammaTory variables:
•	 Leukocytosis	i.e.	WBC	count	>12,000	μL–1
•	 Leukopenia	i.e.	WBC	count	<4000	μL–1
•	 Normal	WBC	count	with	greater	than	10%	immature	forms
•	 Raised	C-reactive	protein
•	 Raised	procalcitonin
c. Tissue hyPoPerfusion
•	 Raised	lactate
•	 Decreased	capillary	refill	time	i.e.	<2seconds
These criteria are based on the 2001 SCCM/eSICM/ACCP/
AtS/SIS International Sepsis Deﬁnitions Conference. Levy et 
al specifically point that rather than giving a specific number 
of criteria that must be reached, “The use of the word “some” 
reflects the clinical reality at the bedside, rather than an arbitrary 
list invented for the purpose of clinical trial entry criteria”. Sepsis 
accompanied by evidence of acute organ dysfunction or tissue 
hypoperfusion is defined as severe sepsis. examples of acute organ 
dysfunction include decreased urine output despite adequate fluid 
resuscitation, coagulopathy, raised bilirubin and acute lung injury. 
Sepsis	accompanied	by	a	systolic	blood	pressure	(SBP)	<	90	mm	
Hg,	SBP	decrease	>	40mm	Hg	or	the	need	for	vasopressors	in	the	
absence of other causes of hypotension and despite adequate fluid 
resuscitation is known as septic shock.3-5
managing sePsis – general & sPecific measures
a. general measures
i. Fluids & monitoring
 Initial resuscitation should be protocolized, quantitative, and 
started as soon as tissue hypoperfusion is recognized. Whether 
crystalloids or colloids are better for resuscitation remains 
a much debated, but unresolved question. The “Surviving 
Sepsis Campaign – Guidelines” (SSCG) recommend the use 
of crystalloids based on the absence of any clear benefit from 
colloids together with the expense associated with colloid 
solutions. Human albuminis now rarely used following 
a Cochrane meta-analysis showing an excess mortality 
associated with its use.6
 During the first six hours of resuscitation the goals of therapy 
should be:
•	 Central	Venous	Pressure	(CVP)	8-12mm	Hg
•	 Mean	Arterial	Pressure	(MAP)	>65	mm	Hg
•	 Urine	output	>0.5ml/kg/hr
•	 Superior	vena	cava	oxygenation	saturation	70%
 These end points are based on a randomized single-centre 
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study, which showed improved survival with targeting of 
these goals.7 This “early goal-directed therapy” strategy 
also showed improved survival in a multicentre trial in 
China.8 New methods for measuring the adequacy of fluid 
resuscitation such as esophageal Doppler, pulse contour 
analysis, and stroke volume variation in ventilated patients 
are used in some centers, but clinical endpoints remain 
useful: blood pressure, heart rate, lactate, base deficit, 
urine output, mixed venous saturation and central venous 
pressure. Pulmonary artery catheters have been shown to 
result in neither harm, nor benefit.9
ii. Vasopressors
 Vasopressor therapy is required to maintain tissue perfusion 
and should be started even when hypovolemia has not yet 
been resolved. SSCG recommend that vasopressor therapy 
should target a mean arterial pressure (MAP) of 65mmHg; 
they also recommend norepinephrine as the first choice of 
vasopressor, with epinephrine being added if an additional 
agent is required. The use of Dopamine as a vasopressor 
was previously widespread, however modern advice is 
that Dopamine should be used only in highly selected 
patients i.e. those with a relative bradycardia and at low risk 
fortachyarrhythmias.4,10
iii. Inotropes
 A trial of dobutamine infusion should be carried out 
in the presence of (a) myocardial dysfunction and low 
cardiac output, (b) tissue hypoperfusion despite adequate 
intravascular volume and arterial pressures. However large 
prospective trials have shown that using dobutamine to 
increase oxygen delivery to supranormal levels does not 
result in any benefit.11
iv. Blood products
 In 1999 the results of the “transfusion Requirements in 
Critical Care trial” published in the New england Journal of 
Medicine, suggested that there is no increased mortality with 
a hemoglobin level of 7 to 9 g/dL, when compared with 10 to 
12 g/dL. Thus, in the absence of specific circumstances such 
as ischemic heart disease or acute hemorrhage, the target 
range for red cell transfusion should be 7 to 9g/dL.12
b. sPecific measures
i. Antimicrobials and diagnosis
 Although antimicrobial therapy should never be delayed 
to obtain samples, obtaining samples prior to therapy is 
essential in obtaining useful cultures. two or more blood 
cultures should be taken. If present at least one culture 
should be taken through each lumen of indwelling devices. 
If cultures from a vascular device are positive much earlier 
than the peripheral cultures this suggests that the device 
may be the source of infection.13 Prompt, appropriate 
antimicrobial therapy is the backbone of the management of 
sepsis. A treatment delay in hypotensive patients increases 
mortality by 7.6% per hour.14 even without shock there is 
a lot of evidence supporting giving early antibiotics.15 The 
SSCG identify starting intravenous antimicrobials within the 
first hour of recognition of or severe sepsis or septic shock as 
one of the goals of therapy.
ii. Corticosteroids
 A French multicenter randomized controlled trial showed that 
hydrocortisone therapy in vasopressor-unresponsive septic 
shock resulted in significant shock reversal and reduction 
in mortality in patients with relative adrenal insufficiency.16 
The CoRtICuS trial enrolled patients without sustained 
shock, and in these patients hydrocortisone did not result in 
decreased mortality.17 on this basis the SSCG recommend 
intravenous hydrocortisone only in patients where fluid and 
vasopressor therapy fail to restore hemodynamic stability. 
However there is no empirical evidence to guide the cessation 
and duration of therapy.
PrevenTion anD early recogniTion of sePsis
Sepsis-related mortality has decreased and outcomes of sepsis 
have also improved with earlier identification. Reducing the 
time of diagnosis appears to be the key step in preventing the 
progression of sepsis. Screening for sepsis in Intensive Care unit 
environments has been shown to decrease mortality.18 Careful 
infection control practices should be instituted and include hand 
washing, catheter care, barrier precautions, airway management, 
head-of-bed elevation and subglottic suctioning.19 The role of 
selective oral decontamination (SoD) and selective digestive 
decontamination (SDD) remain somewhat controversial. overall, 
the data relating to the latter techniques show a slight reduction 
in ventilator-associated pneumonia, but no change to overall 
mortality.20
fuTure TheraPies in sePsis
The high mortality in sepsis means that new therapies are 
always being looked at, as even small decreases in mortality will 
result in many lives saved. Statins are well-recognized to have anti-
inflammatory properties and in murine models they have shown 
to prolong survival, however as yet this has not undergone any 
human RCt.21 Human immunoglobulin has also been investigated 
as a therapy in sepsis. The concept is that anti-endotoxin antibody 
cross reactivity will reduce the inflammatory response. However 
one meta-analysis concluded that, as yet, there is insufficient 
evidence for intravenous immunoglobulin to be used outside 
trials.22 other inflammatory response mediators include the 
high-mobility group box protein 1 (HMGB-1) protein that acts 
as a transcriptional cofactor and has a potent inflammatory 
cascade effect in sepsis. In rodent models, antagonism of HMGB-
1 improves mortality. ethyl pyruvate has been shown to suppress 
these abnormal biochemical markers including HMGB-1, and 
may therefore have a role in the treatment of sepsis. ethyl pyruvate 
has undergone phase 2 clinical trials in patients undergoing 
cardiopulmonary bypass, but no results have yet been published.23
conclusion
While exciting new therapies are being developed, sepsis 
care bundles, such as those introduced by the Surviving Sepsis 
Campaign Guidelines, remind us that the key to reducing 
mortality remains good clinical judgment with early diagnosis, 
taking appropriate samples preceding broad-spectrum antibiotic 
treatment tailored by local protocols, and aggressive circulatory 
support.  ref
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